RT Journal Article
SR Electronic
T1 Association of coffee consumption in metabolic syndrome: a cross-sectional and Mendelian randomization study in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.11.23293897
DO 10.1101/2023.08.11.23293897
A1 Tommy Hon Ting Wong
A1 Shan Luo
A1 Shiu Lun Au Yeung
A1 Jimmy Chun Yu Louie
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.08.11.23293897.abstract
AB Objective To investigate the associations between coffee consumption and metabolic syndrome and its component conditions, as well as the effect of using milk, sugar, and artificial sweetener on these associations.Research Design and Methods The cross-sectional analysis included 351,805 participants from the UK Biobank. Coffee consumption data was obtained using food frequency questionnaire and 24-hour recall and metabolic syndrome was ascertained based on blood biochemistry results and self-reported medication use. Odds ratios were calculated using multivariable logistic regression adjusted for lifestyle and socioeconomic factors, with verification using two-sample Mendelian randomization.Results Coffee consumption up to 2 cups per day was inversely associated with metabolic syndrome (1 cup/day, OR: 0.88, 95% CI: 0.85, 0.92; 2 cups/day, OR: 0.90, 95% CI: 0.86, 0.93) while associations at higher intakes were near null. Mendelian randomization did not support a causal association between coffee intake and metabolic syndrome. Both self-reported and genetically predicted high coffee consumption (4 cups per day or more) were associated with central obesity. The inverse association between coffee consumption and metabolic syndrome was more profound among drinkers of ground coffee than those of instant coffee. Results were similar when stratified by the use of milk and sugar, yet the use of artificial sweetener with coffee was positively associated with metabolic syndrome and all component conditions.Conclusions Coffee consumption likely increase the risk of central obesity but unlikely impact risk of metabolic syndrome. The possible health effect of using artificial sweetener with coffee warrant investigations in future studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by an internal grant from the Faculty of Science, The University of Hong Kong.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank project was approved by the National Information Governance Board for Health and Social Care and the NHS North West Multicenter Research Ethics Committee (reference number: 11/NW/0382). Written consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study can be requested via application to UK Biobank (https://www.ukbiobank.ac.uk).